Equillium Inc

EQNASDAQ · USD
1.89USD+0.03 (+1.89%)
237

Equillium Inc (EQ) Covered Calls

As of September 16, 2026, EQ has 3 covered call opportunities in the coming three months. Return ranges from 47.8 to 171.5% until expiration. Annualized return ranges from 87.0 to 295.3%. The nearest expiration is January 15, 2027. Maximum potential profit is $319.

Read more

Running EQ covered calls helps you generate consistent income from Equillium Inc's shares you already own, turning a long stock position into a yield-producing asset. A covered call on Equillium Inc involves holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike price. Use our scanner to find the best EQ covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.

A covered call is one of the most widely used options strategies because it pairs limited risk with a clear income profile: if EQ stays below the strike at expiration, you keep the premium and the shares; if it rises above, you deliver the stock at the strike and still pocket the premium. Selling EQ covered calls works best when implied volatility is elevated, since richer premiums improve the risk-reward. Key inputs to evaluate include strike selection relative to delta, days to expiration, annualized return, and the probability of assignment — all of which determine whether a given Equillium Inc covered call is worth writing.

Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase Ib clinical trial for the treatment of asthma disease; and Phase Ib clinical trial for the treatment of and lupus nephritis. It also develops EQ101 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ102 to treat various gastrointestinal diseases.

The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.

Income-focused investors, long-term EQ holders, and systematic premium sellers all face the same challenge: finding the covered call strike and expiry that balances yield against the risk of being called away. Our scanner ranks covered calls by annualized return, downside protection, and probability of profit, so selling EQ covered calls becomes a measured decision instead of a guess. Stop eyeballing the chain — let the best Equillium Inc covered calls come to you, already filtered for the metrics that matter.

Stock Statistics

  • IndustryBiotechnology
  • SectorHealthcare
  • IV percentile0.79% Subdued
  • Market cap (M$)118
  • 52 weeks high-47.46%
  • 52 weeks low144.74%
  • Analyst recommendationStrong Buy
    1.00
  • Target price$8.60
    355.03% above the current stock price
  • Dividend
  • Payout ratio
  • Earnings date2026-11-12
  • P/E
  • Future P/E
  • EPS (ttm)-0.20
  • EPS growth next 5 years11.40%

As of September 16, 2026

2027-04-162125.00168.820.051.00319.00171.51295.28-2.69+0.5020.95
2027-01-151212.5034.410.251.0589.0047.85144.34-13.44+0.623340.80
2027-04-162122.5034.410.301.5094.0050.5487.01-16.13+0.71101.20

As of September 16, 2026

Sell covered calls with the data behind you

Find the best EQ covered call setups ranked by annualized return, filter by premium, delta, and days to expiration, and act on the opportunity in seconds.

Start your 14-day free trial